ApraglutideGLP-2 analogue in clinical research
Apraglutide is being studied for short bowel syndrome, where the remaining intestine cannot absorb enough fluid or nutrients. Its aim is practical: reduce the burden of intravenous support.
What is Apraglutide?
Apraglutide is a long-acting GLP-2 analogue investigated for short bowel syndrome and intestinal failure.
How it works
GLP-2 signalling aims to improve absorption by the remaining intestine, potentially reducing dependence on intravenous fluid or nutrition.
Effects studied
Parenteral-support requirements
Clinical programmes examine whether intravenous support can be reduced. Remaining bowel anatomy, including whether the colon is present, affects interpretation. 1 2
Evidence: A disease-specific clinical-development question; reduced support and complete independence are separate endpoints.
What does the evidence show?
Short bowel syndrome clinical programme; archived references retained
A treatment for lost absorptive capacity
Short bowel syndrome often follows extensive intestinal surgery. How much the remaining bowel can absorb matters as well as how much someone eats. Apraglutide is a long-acting analogue of glucagon-like peptide-2, a hormone involved in intestinal adaptation and absorption.
What researchers measure
Trials examine changes in parenteral support: fluid or nutrition delivered through a vein. Weekly volume, days connected to an infusion and complete independence are related but different outcomes. Describing all three as “recovery” loses information that matters to patients.
Anatomy can change the answer
A person with part of the colon still connected may have different fluid and nutrient handling from someone without it. The archived programme includes studies examining these clinical differences. Results need to be read alongside the participants’ anatomy and their initial support needs. One average cannot describe every case.
Adjusting care as absorption changes
Hydration, electrolytes, nutritional status and the support prescription need to be reviewed as intestinal absorption changes. Gastrointestinal symptoms and potential effects on intestinal growth also require study. The relevant question is whether the treatment reduces dependence safely under specialist care. It is not evidence for using GLP-2 analogues to treat ordinary digestive discomfort or improve an otherwise normally functioning bowel.
Safety & status
Fluid, electrolyte and nutritional status need careful assessment. Gastrointestinal effects and concerns related to intestinal growth are relevant to evaluating this treatment class.
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Is it intended for ordinary poor digestion?
No. Its development context is short bowel syndrome with major absorption problems.
Why does bowel anatomy matter?
The amount and type of remaining intestine influence absorption and the need for parenteral support.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Apraglutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Apraglutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.